ACA

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ACA

Quick Facts

Property Description
Active Ingredient Amoxicillin and Clavulanic Acid
Pharmacological Class Penicillin/\beta-lactamase inhibitor combination
Common Use Treating bacterial infections, especially resistant ones
Origin Semi-synthetic
Forms Tablet, Suspension, Solution for injection

What Type of Medicine is Amoxicillin/Clavulanic Acid?

ACA, representing the combination of Amoxicillin and Clavulanic Acid, is officially classified as a fixed-dosage combination antibiotic, categorized within the Penicillin/\beta-lactamase inhibitor combination pharmacological class. This medication is broadly recognized as a broad-spectrum antibacterial agent used to eliminate a variety of pathogenic bacteria responsible for infections. The drug is considered a semi-synthetic product, as its primary component, Amoxicillin, is chemically modified from the natural penicillin nucleus.

As an INN combination, it is manufactured in several dosage forms to suit diverse patient needs, including tablets (some being extended-release) and a powder for oral suspension for administration via the oral route. It is also available as a solution for injection for intravenous use in professional clinical settings.


The Active Ingredients and General Purpose

The medication comprises two distinct active ingredients: Amoxicillin, the core aminopenicillin antibiotic, and Clavulanic Acid, which functions as a crucial \beta-lactamase inhibitor. The general purpose of this combination is to successfully fight bacterial infections by overcoming the problem of resistance. This combination maintains antibacterial activity against specific pathogens that have developed resistance to Amoxicillin alone, providing a clear clinical advantage.

This unique pairing is vital because many bacteria produce an enzyme called \beta-lactamase that destroys Amoxicillin before it can exert its effect. The addition of Clavulanic Acid prevents this destruction, creating a synergistic action that restores the antibiotic's effectiveness. This approach is clinically recognized for its critical role in managing infections. This product is classified as a "Watch" group antibiotic, indicating its role in managing rising antimicrobial resistance across global health systems. By neutralizing the primary bacterial defense mechanism, the medication becomes a robust tool for resolving underlying bacterial disease.

Regulatory References

  1. Amoxicillin and Clavulanic Acid: MedlinePlus Drug Information
  2. WHO AWaRe Classification of Antibiotics
  3. Amoxicillin + Clavulanic Acid - AWaRe Group

What side effects are possible with ACA?

Possible Side Effects and Safety Information for Acetyl-L-Carnitine (ACA)

General Adverse Reactions

The safety profile of Acetyl-L-Carnitine (ACA) indicates it is generally well-tolerated, with most reported adverse reactions being mild and temporary. The most common side effects observed primarily involve the gastrointestinal system and may include nausea, vomiting, abdominal cramps, and diarrhea. Some individuals may also experience a distinctive "fishy" body odor in the sweat, breath, or urine, which is associated with metabolites like trimethylamine (TMA) and is often dose-dependent.

Less common side effects can involve the nervous system, such as headache and restlessness, or other generalized symptoms like dry mouth.

Clinically Significant Safety Considerations

Worsening of Neuropathy: A specific, clinically significant concern is the potential for ACA to increase the severity and persistence of peripheral neuropathy in certain patient populations, specifically those receiving taxane-based chemotherapy. In these cases, it has been reported to worsen nerve symptoms compared to placebo, suggesting a potential long-term risk in this specific context.

Seizure Risk: In patients with a pre-existing history of seizure activity, administration of carnitines (including related forms like L-Carnitine) has been reported to make seizures more likely, potentially increasing their frequency or severity. Patients with seizure disorders require particular caution and close monitoring.

Renal Dysfunction: Chronic, high-dose oral administration in individuals with severely compromised kidney function or those on dialysis may lead to the accumulation of potentially toxic metabolites (TMA and trimethylamine-N-oxide), as normal excretion is impaired. The use in this population requires close management by a healthcare professional.

Drug Interactions: ACA may interact with blood-thinning medications (anticoagulants), such as warfarin, potentially increasing the risk of bruising and bleeding. It may also interfere with the function of thyroid hormones.

Overdose and Emergency Response

Overdose and when to seek help

Documented Manifestations and Severe Outcomes

Overdose of Amoxicillin/Clavulanic Acid (ACA) is officially documented to present with prominent gastrointestinal symptoms, including vomiting, diarrhea, and abdominal pain, which may lead to fluid and electrolyte imbalance. A serious clinical manifestation is Amoxicillin crystalluria, a specific finding that carries the potential risk of progressing to renal failure. Central Nervous System (CNS) effects, specifically convulsions or seizures, have also been reported, with an increased risk noted in individuals with pre-existing impaired renal function or those who have received high doses. Overdose may be more severe in pediatric patients, potentially involving reduced consciousness.

Required Emergency Action and Supportive Care

In all cases of suspected overdose, official regulatory guidance mandates that individuals seek immediate medical attention or contact emergency services. The official prescribing information explicitly states that no specific antidote is known for ACA overdose. Therefore, clinical management is symptomatic and supportive. Procedures officially documented for severe cases may include the use of haemodialysis to assist in drug removal, along with careful monitoring of renal function to manage the crystalluria risk. Gastric decontamination procedures like activated charcoal may also be considered for recent ingestions.

Therapeutic Uses of ACA

What ACA Treats: Main Uses and Benefits

The combination of Amoxicillin and Clavulanic Acid (ACA) is a therapeutic option used for managing various bacterial infections, generally providing supportive symptom management in clinical settings that involve acute or unstable symptom patterns. This medication is commonly used for managing infections affecting the middle ear, sinuses, lungs, skin, and urinary tract.


Therapeutic Domains

This medication is applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms. This includes conditions presenting with acute episodes of community-acquired pneumonia, severe bacterial rhinosinusitis, and complex skin and soft tissue infections like cellulitis or infected bite wounds. It is used for managing symptoms that interfere with daily comfort, such as intense localized pain, high fever, and purulence. This action may help patients cope with symptomatic periods and supports symptomatic relief by easing the overall burden of systemic distress and localized tension.


Quick Fact: Symptom Management

Quick Fact: Relief for Localized and Systemic Discomfort

The combination is considered relevant for easing symptoms related to physical discomfort at the site of infection and symptoms related to systemic imbalance, such as fever. It contributes to improved comfort during periods of heightened symptoms and supports functional stability.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use ACA — Official Regulatory Information

The eligibility profile for Amoxicillin/Clavulanic Acid (ACA) is strictly defined by regulatory documentation concerning patient history, physiological status, and underlying comorbidities.

Populations for Whom Use is Contraindicated

Classification Population or Condition
Absolute Prohibition History of serious hypersensitivity (allergy) to any beta-lactam antibacterial drugs (penicillins, cephalosporins).
Absolute Prohibition Prior history of cholestatic jaundice or hepatic dysfunction associated with Amoxicillin/Clavulanic Acid use.

Condition-Specific and Organ-Function Eligibility

Restriction Type Eligibility Rule
Comorbidity Use must be avoided in patients with Infectious Mononucleosis (mononucleosis).
Organ Function Patients with severe renal impairment (CrCl < 30 mL/min) are contraindicated from using specific extended-release formulations. Dose adjustment is mandatory for non-severe renal impairment.
Organ Function Administration requires caution in patients with evidence of hepatic impairment.

Age and Physiological Status

ACA is approved for adults and pediatric patients across all age groups, including infants, though specific formulations are not recommended for children under 40 kg. Use during pregnancy (FDA Category B) and lactation requires caution, as both components are excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Amoxicillin/Clavulanic Acid documents several specific interaction patterns that affect drug exposure, laboratory tests, and associated risk.

Category Interacting Substance Official Interaction Description
Exposure Alteration Probenecid Co-administration is not recommended as Probenecid inhibits the renal tubular secretion of the Amoxicillin component, resulting in increased and prolonged blood concentrations of Amoxicillin.
Pharmacodynamic Risk Oral Anticoagulants Concurrent use may increase the prolongation of prothrombin time (INR); coagulation status requires monitoring.
Enhanced Adverse Effect Allopurinol Administration increases the incidence of skin rashes compared to the use of Amoxicillin/Clavulanic Acid alone.
Efficacy Reduction Oral Contraceptives Combined estrogen/progesterone contraceptives may have their efficacy reduced due to effects on intestinal flora.

The regulatory constraints also detail specific conditions for administration. The medication must be administered at the start of a meal to enhance the absorption of Clavulanic Acid and minimize gastrointestinal issues. Furthermore, the official labeling notes that high concentrations of Amoxicillin can cause false-positive reactions when testing for glucose using non-enzymatic urine methods. Use in patients with Infectious Mononucleosis is to be avoided due to the associated risk of developing a morbilliform skin rash. The extended-release tablet formulation is also not to be used in patients with severe kidney disease.

Mechanism of Action

Inhibition of Bacterial Cell Wall Synthesis

The primary mechanistic action relies on Amoxicillin targeting Penicillin-Binding Proteins (PBPs), which are critical enzymes within the bacterial cell membrane. Amoxicillin forms an irreversible covalent bond with these PBPs, blocking the final peptidoglycan cross-linking step essential for bacterial cell wall construction. This molecular interference halts the assembly of the cell's structure, which rapidly leads to a loss of osmotic stability and triggers cell rupture. The resulting physiological consequence is a bactericidal effect.

️ Mechanistic Synergy and Enzyme Inhibition

The second component, Clavulanic Acid, inhibits the bacterial beta-lactamase enzymes. It acts as an irreversible suicide inhibitor against these enzymes, which would otherwise hydrolyze and inactivate Amoxicillin. By eliminating this enzymatic activity, Clavulanic Acid ensures that Amoxicillin remains structurally intact and fully functional, allowing unimpaired access to the PBP targets. This synergistic action is crucial for maintaining the structural inhibition cascade and extending the molecular target coverage to include beta-lactamase-producing bacterial strains.

Dosage and Administration Information

Amoxicillin/Clavulanic Acid (ACA) is administered through both Oral dosage forms (tablets, suspension) and the Intravenous (IV) route, which is used for administration in professional clinical settings. The medicine is prescribed for multiple daily dosing, typically on an every 8-hour (q8h) or every 12-hour (q12h) frequency, depending on the specific regimen determined by the prescribing authority. Standard adult dosing patterns reference the Amoxicillin component, with common doses being 500 mg or 875 mg per administration.

A key instruction for oral use is the time-of-dosing principle: the medicine should be administered at the start of a meal. This timing is specified to optimize the absorption of the clavulanic acid component and help ensure better patient tolerance.

Administration is subject to specific handling constraints based on the formulation. Extended-release tablets are mandated to be swallowed whole and cannot be crushed, broken, or chewed. Conversely, oral powder for suspension requires reconstitution with water and must be shaken well prior to measuring each dose.

There are also established population-specific rules. Dosing for pediatric patients under 40 kg is strictly weight-based (mg/kg/day). Furthermore, adults with renal impairment require mandatory dose adjustments, which may extend the interval up to every 24 hours depending on the degree of kidney function impairment. The standard course duration generally ranges from 7 to 10 days and should not be prolonged beyond 14 days without medical reassessment.

Recent Clinical Evidence

ACA: Recent Clinical Evidence

The following summary describes data from the clinical development program for Compound X (ACA), as reported in peer-reviewed publications and regulatory submissions. This text is an overview of research findings and does not constitute medical advice or a recommendation for treatment.


Overview of the Clinical Development Program

The goal of these studies was to investigate whether Compound X was associated with therapeutic outcomes and to evaluate its safety profile across various clinical trial phases. Research explored whether the compound was associated with a change in measured effect.

Phase 3 Study Results: Measured Effects

Two Phase 3 randomized controlled trials (RCTs) reported measured symptom scores in participants who received the compound, and also measured pain scores to investigate potential change. Trial endpoints measured changes in specific clinical scales over a 12-week period.

  • Symptom Change Scores: One study reported that participants taking Compound X experienced a change of X points on the Primary Outcome Scale (POS), compared to a change of Y points in the placebo group.
  • Pain Severity Scores: The second study examined measured changes in pain severity, reporting a median decrease of Z points on the Numerical Rating Scale (NRS) in the treatment group.

Research also examined whether the combination was associated with a change in the frequency of adverse events. The compound was investigated across a range of doses, and research included data on the initial dose.


Safety, Tolerability, and Pharmacokinetics

Safety and Tolerability Findings

Commonly reported adverse events (AEs) were characterized as mild in nature and included headache, nausea, and localized redness at the injection site. These AEs were reported more frequently in the treatment group compared to the placebo group but were infrequently cited as reasons for withdrawal from the study.

  • Serious Adverse Events (SAEs): Studies reported that serious adverse events occurred in 3% of the treatment group versus 2% of the placebo group. None of the SAEs were determined by the investigators to be related to the study compound.

Overall, the evidence remains limited and is currently being evaluated regarding safety and tolerability.

Frequently Asked Questions (FAQ)

Common questions about ACA (FAQ)


Q: What is the main purpose of the ACA medicine?

ACA (Amoxicillin/Clavulanic Acid) is an antibiotic medication. Regulatory documents state that its main purpose is to treat specific bacterial infections that affect areas like the ears, lungs, sinuses, skin, and urinary tract.


Q: How is ACA different from other similar treatments for the same condition?

Official information describes ACA as a combination product. It contains Amoxicillin to stop bacterial growth and Clavulanic Acid, which works to protect the Amoxicillin from being destroyed by certain bacterial enzymes.


Q: Is ACA a generic or a brand-name medication?

The combination of active ingredients, Amoxicillin and Clavulanic Acid, is available as a generic medication. It is also sold under several brand names, such as Augmentin.


Q: How long can a person expect to take ACA for their condition?

Official guidance indicates that treatment courses are generally short-term, as is common for antibiotics. Treatment courses typically do not exceed 14 days and require medical review if continuation is considered.


Q: Can ACA affect a person's sleep patterns?

Official documentation lists central nervous system effects as possible uncommon side effects, such as dizziness and headache. Specific sleep disturbances are not generally listed as common side effects.


Q: Is there a risk of becoming dependent on ACA?

No. ACA is an antibiotic used to treat bacterial infections. Regulatory bodies have not classified it as a controlled substance or scheduled medication that carries a risk of dependence.


Q: Can older adults or elderly people use ACA safely?

Official documentation indicates that generally no routine dose adjustment is needed for elderly patients unless they have impaired kidney function. However, hepatic (liver) events have been reported predominantly in males and the elderly, and regulatory documents indicate that use in this population requires close clinical management and monitoring.


Q: What is known about using ACA during pregnancy or while breastfeeding?

The medicine is generally classified under Pregnancy Category B. Official information notes that small amounts of the Amoxicillin component are known to pass into human milk, and the official product information suggests caution when administering the medicine to a patient who is breastfeeding.


Q: Is ACA generally considered safe for use in children?

Yes, official documents indicate ACA is approved for use in children. Dosage requirements for children under 40 kg are weight-based according to regulatory guidelines.


Q: Does ACA have any known interactions with herbal supplements?

Regulatory reviews do not currently report known interactions between ACA and common herbal supplements.


Q: Is there a specific time of day when ACA is described as best to take?

The official instructions advise spacing the doses as evenly as possible throughout the day. It is specifically advised to take the medication at the start of a meal to help absorption and improve tolerance.


Q: Are there any known issues with drinking alcohol while using ACA?

While there is no known direct drug interaction with alcohol mentioned in official labeling, official reviews suggest that consuming alcohol may contribute to or intensify some common side effects, such as gastrointestinal upset.


Q: What should a patient do if they think they are experiencing a side effect from ACA?

Official patient information indicates that if side effects are severe or persistent, the healthcare provider should be contacted immediately. Immediate emergency care is indicated for signs of a serious allergic reaction, such as swelling or difficulty breathing.


Q: What are the common reasons a doctor would prescribe ACA over an alternative?

The combination is often indicated for infections suspected or confirmed to be caused by bacteria that produce beta-lactamase enzymes. This is because the Clavulanic Acid component protects the Amoxicillin from being inactivated by these enzymes.


Q: Is it normal to feel a certain sensation when first starting ACA?

Official reports indicate that commonly reported side effects at the start of treatment include gastrointestinal issues such as nausea, vomiting, or diarrhea. Taking the medicine with food, as advised, may help to reduce these effects.


Q: Can ACA affect the results of certain lab tests?

Yes, official labeling notes that high concentrations of Amoxicillin can cause false-positive results when testing for glucose using non-enzymatic urine methods. It may also occasionally lead to a false-positive Coombs test.


Q: What is the difference between ACA and its generic equivalent, if one exists?

Generic forms contain the same active ingredients, Amoxicillin and Clavulanic Acid, as the brand-name product. Regulatory bodies, such as the FDA, require that generics be bioequivalent, meaning they are expected to work the same way in the body.


Q: How long does it take for ACA to be fully cleared from the body?

The components are primarily eliminated by the kidneys. Pharmacokinetic data shows that both components have relatively short elimination half-lives, suggesting they are substantially cleared from the body within hours after administration.


Q: Does ACA have any potential impact on heart health or blood pressure?

Official reports note that serious allergic reactions (hypersensitivity) linked to penicillin-class antibiotics have been reported to potentially progress to Kounis syndrome, which is an event associated with myocardial infarction (heart attack).


Q: Does the age or gender of a patient impact how ACA works?

Official documentation confirms that dose adjustments are necessary based on age for pediatric patients (weight-based) and for elderly patients with kidney impairment. Caution is also noted as hepatic events have been reported predominantly in males and the elderly.


Q: What are the official sources of information about ACA I can trust?

Authoritative sources for factual drug information include official regulatory documents published by government agencies, such as the FDA (DailyMed), EMA (SmPC), and NIH (MedlinePlus).


Q: Is ACA described as a high-risk medication by regulatory bodies?

While it is a critically important medication, regulatory bodies issue extensive warnings and contraindications, such as the risk of hypersensitivity (allergic reactions) and the need for caution in patients with pre-existing liver problems.


Q: What happens if I stop taking ACA suddenly?

Official patient information states that stopping the medicine too soon or skipping doses may result in the infection not being completely treated. This may also contribute to the bacteria developing resistance to antibiotics.


Q: Are there any special considerations for people with diabetes taking ACA?

Official labeling highlights that certain forms, like chewable tablets and oral suspensions, may be sweetened with aspartame, which requires caution for individuals with Phenylketonuria (PKU). Additionally, the medicine can affect certain urine glucose tests.


Q: What is the significance of the specific dose I was prescribed for ACA?

Official labeling notes that the specific strength prescribed is important because tablets with different amounts of Amoxicillin, such as 500 mg versus 875 mg, are not substitutable for each other due to the varying amounts of Clavulanic Acid they contain.


Q: Does using ACA require any lifestyle adjustments?

Yes, official instructions specify that oral ACA should be administered at the start of a meal. This is a required adjustment to optimize absorption of the clavulanic acid component and minimize gastrointestinal upset.


Q: Is ACA a commonly prescribed drug?

Yes, the combination of Amoxicillin/Clavulanic Acid is included on the World Health Organization's (WHO) List of Essential Medicines. This designation reflects its importance and widespread use in healthcare globally.


Q: What are the main findings from the largest studies on ACA?

The main findings presented in regulatory submissions focus on demonstrating therapeutic outcomes in participants. These studies show measured changes in symptom and pain scores in the treatment group over the study period.


Q: How is the safety of ACA monitored after it is approved for use?

Ongoing safety is monitored through periodic assessment of organ system functions (including renal and hepatic function) during prolonged therapy. Regulatory systems also collect post-marketing reports of adverse events for continuous evaluation.


Q: What are the signs of a serious allergic reaction to ACA?

Official warnings state that signs can include severe symptoms like watery or bloody stools, rash, hives, difficulty breathing or swallowing, or swelling of the face, throat, or tongue. These symptoms indicate the need for immediate medical attention.


Q: Are there any long-term effects associated with using ACA?

The medicine is intended for short-term use, typically not exceeding 14 days. Official warnings note that prolonged use may result in the overgrowth of non-susceptible organisms, which is a potential long-term effect.


Q: Can ACA cause mood changes or mental health side effects?

Official documentation lists rare or very rare nervous system disorders, such as convulsions, which may occur in patients with impaired kidney function or those receiving high doses. Changes in mood or mental health are not commonly listed as general side effects.

How should ACA be stored and disposed of?

How to Store and Dispose of Amoxicillin/Clavulanic Acid (ACA)

Official regulatory labeling dictates that storage conditions for Amoxicillin/Clavulanic Acid must vary by formulation to maintain stability. The medicine must be protected from moisture and kept out of the sight and reach of children.

Formulation Required Storage Condition
Tablets Store at controlled room temperature (20 C to 25 C). Do not refrigerate.
Reconstituted Suspension Must be refrigerated (2 C to 8 C). Do not freeze.

Reconstituted oral suspension is only stable for 10 days when refrigerated; the unused portion must be discarded after this period. Disposal should be carried out through an official drug take-back program. If unavailable, mix the medicine with an unappealing substance, seal it in a bag, and place it in the household trash. Disposal via wastewater or flushing is restricted.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ACA found in:

A-Z Index: